Anavex Life Sciences
AVXL
48 hedge funds and large institutions have $22.3M invested in Anavex Life Sciences in 2018 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 16 reducing their positions, and 14 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.27% less ownership
Funds ownership: 20.36% → 18.08% (-2.3%)
6% less capital invested
Capital invested by funds: $23.8M → $22.3M (-$1.5M)
16% less funds holding
Funds holding: 57 → 48 (-9)
38% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 16
64% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 14
80% less call options, than puts
Call options by funds: $251K | Put options by funds: $1.28M
Top Buyers
Top Sellers
| 1 |
Goldman Sachs
New York
|
-$571K |
| 2 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$502K |
| 3 |
ECM
Element Capital Management
New York
|
-$378K |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
-$319K |
| 5 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
-$284K |
AVXL Hedge Fund Activity: Q3 2018 in Review
48 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Anavex Life Sciences (AVXL) for Q3 2018, worth a combined $22.3M — down 6.3% from $23.8M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of AVXL and 5 opened new positions — a net loss of 9 holders — while 16 trimmed existing stakes and 10 added.
The largest buyer was Park West Asset Management, adding an estimated $1.41M. The largest seller was Goldman Sachs, cutting an estimated $571K.
- 48 institutional investors held Anavex Life Sciences (AVXL) as of Q3 2018, down from 57 in Q2 2018.
- Funds reported $22.3M of Anavex Life Sciences stock for Q3 2018, down 6.3% quarter-over-quarter.
- 5 funds opened new Anavex Life Sciences positions in Q3 2018 and 14 closed out, a net change of -9 holders.
- The largest Anavex Life Sciences buyer in Q3 2018 was Park West Asset Management, an estimated $1.41M added.
- The largest Anavex Life Sciences seller in Q3 2018 was Goldman Sachs, an estimated $571K sold.
Based on aggregated 13F filings for Q3 2018.